Stock DNA
Pharmaceuticals & Biotechnology
CNY 909 Million (Micro Cap)
9.00
NA
0.00%
-0.57
7.21%
0.68
Revenue and Profits:
Net Sales:
122 Million
(Quarterly Results - Jun 2025)
Net Profit:
25 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
32.89%
0%
32.89%
6 Months
36.24%
0%
36.24%
1 Year
77.37%
0%
77.37%
2 Years
-11.83%
0%
-11.83%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Nanjing Medlander Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.70%
EBIT Growth (5y)
-1.27%
EBIT to Interest (avg)
72.17
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.27
Tax Ratio
12.71%
Dividend Payout Ratio
78.76%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
29.08%
ROE (avg)
7.41%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.68
EV to EBIT
1.81
EV to EBITDA
1.30
EV to Capital Employed
0.25
EV to Sales
0.33
PEG Ratio
0.35
Dividend Yield
NA
ROCE (Latest)
13.82%
ROE (Latest)
7.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
121.80
122.50
-0.57%
Operating Profit (PBDIT) excl Other Income
33.10
41.80
-20.81%
Interest
0.30
0.30
Exceptional Items
0.10
0.80
-87.50%
Consolidate Net Profit
25.10
37.70
-33.42%
Operating Profit Margin (Excl OI)
206.50%
284.60%
-7.81%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -0.57% vs 30.74% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -33.42% vs 38.10% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
419.80
335.90
24.98%
Operating Profit (PBDIT) excl Other Income
131.80
85.70
53.79%
Interest
1.10
0.50
120.00%
Exceptional Items
-8.80
0.70
-1,357.14%
Consolidate Net Profit
108.90
92.50
17.73%
Operating Profit Margin (Excl OI)
245.00%
195.20%
4.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 24.98% vs -9.85% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.73% vs -28.46% in Dec 2023
About Nanjing Medlander Medical Technology Co., Ltd. 
Nanjing Medlander Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






